| 1 |
34297159 | Effect of ibrutinib on CCR7 expression and functionality in chronic lymphocytic leukemia and its implication for the activity of CAP-100, a novel therapeutic anti-CCR7 antibody. | 2022 Mar |
1 |
| 2 |
34332791 | Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax. | 2022 Feb |
1 |
| 3 |
34615723 | Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring. | 2022 Jan 1 |
1 |
| 4 |
34674984 | Bing-Neel Syndrome: Update on the Diagnosis and Treatment. | 2022 Mar |
1 |
| 5 |
34725904 | Tumor-Cell-Specific Targeting of Ibrutinib: Introducing Electrostatic Antibody-Inhibitor Conjugates (AiCs). | 2022 Jan 3 |
1 |
| 6 |
34726785 | Ibrutinib skin toxicities: Report of two cases. | 2022 Apr |
1 |
| 7 |
34732527 | Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells. | 2022 Jan |
2 |
| 8 |
34795418 | Inhibitors of Bcl-2 and Bruton's tyrosine kinase synergize to abrogate diffuse large B-cell lymphoma growth in vitro and in orthotopic xenotransplantation models. | 2022 Apr |
1 |
| 9 |
34839996 | Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib. | 2022 Feb 5 |
2 |
| 10 |
34882824 | Haemorrhagic bullae and purpura associated with the Bruton tyrosine kinase inhibitor ibrutinib. | 2022 Feb |
1 |
| 11 |
34890967 | REC8 enhances stemness and promotes metastasis of colorectal cancer through BTK/Akt/β-catenin signaling pathway. | 2022 Jan |
2 |
| 12 |
34954235 | The Conformational State of the BTK Substrate PLCγ Contributes to Ibrutinib Resistance. | 2022 Mar 15 |
3 |
| 13 |
34994565 | Impact of Solvent-Drug Interactions on the Desolvation of a Pharmaceutical Solvate. | 2022 Jan 20 |
2 |
| 14 |
35008919 | Role of Tyrosine Kinase Syk in Thrombus Stabilisation at High Shear. | 2022 Jan 1 |
1 |
| 15 |
35076567 | Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review. | 2022 Jan 11 |
2 |
| 16 |
35096069 | Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia). | 2022 |
2 |
| 17 |
35115740 | Ibrutinib in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Retrospective Study. | 2022 Jan |
2 |
| 18 |
35123927 | Managing Relapsed Mantle Cell Lymphoma. | 2022 Jan 11 |
2 |
| 19 |
35159041 | The Role of Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions. | 2022 Feb 2 |
2 |
| 20 |
35169086 | [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma]. | 2022 Jan |
1 |
| 21 |
35179349 | Depleting Tumor Infiltrating B Cells to Boost Antitumor Immunity with Tumor Immune-Microenvironment Reshaped Hybrid Nanocage. | 2022 Mar 22 |
2 |
| 22 |
35188143 | Research progress in overcoming ibrutinib drug resistance. | 2022 Feb |
2 |
| 23 |
35227147 | Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. | 2022 Feb 28 |
1 |
| 24 |
35243171 | Cystoid macular edema secondary to ibrutinib. | 2022 Jun |
2 |
| 25 |
35247800 | The effect of Bruton's tyrosine kinase inhibitor ibrutinib on atherothrombus formation under stenotic flow conditions. | 2022 Apr |
2 |
| 26 |
35296194 | Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia. | 2022 Mar |
2 |
| 27 |
35326604 | DLBCL 1L-What to Expect beyond R-CHOP? | 2022 Mar 11 |
2 |
| 28 |
35349631 | Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia. | 2022 Mar 29 |
2 |
| 29 |
35357653 | New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia. | 2022 Jun |
1 |
| 30 |
35377947 | Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. | 2022 Jun 14 |
1 |
| 31 |
35379357 | Combining BTK inhibitors with BCL2 inhibitors for treating chronic lymphocytic leukemia and mantle cell lymphoma. | 2022 Apr 4 |
1 |
| 32 |
35404729 | Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. | 2022 May |
1 |
| 33 |
35406532 | Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group. | 2022 Mar 30 |
1 |
| 34 |
35437106 | Cardiotoxicity of BTK inhibitors: ibrutinib and beyond. | 2022 Apr |
1 |
| 35 |
35440579 | A loss-of-adhesion CRISPR-Cas9 screening platform to identify cell adhesion-regulatory proteins and signaling pathways. | 2022 Apr 19 |
2 |
| 36 |
35443042 | Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease. | 2022 Apr 20 |
1 |
| 37 |
35448150 | Ibrutinib in c-MYC and HER2 Amplified Oesophagogastric Carcinoma: Results of the Proof-of-Concept iMYC Study. | 2022 Mar 22 |
1 |
| 38 |
35449638 | Reversible Systolic Heart Failure in a Patient on Ibrutinib Chemotherapy. | 2022 Mar |
1 |
| 39 |
35454970 | Targeting Specific Checkpoints in the Management of SARS-CoV-2 Induced Cytokine Storm. | 2022 Mar 25 |
2 |
| 40 |
35456016 | Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions. | 2022 Apr 14 |
4 |
| 41 |
35465824 | The role of BTK inhibitors on the tumor microenvironment in CLL. | 2022 Apr 23 |
4 |
| 42 |
35476648 | Subclonal evolution of CLL driver mutations is associated with relapse in ibrutinib and acalabrutinib treated patients. | 2022 Apr 27 |
1 |
| 43 |
35493119 | Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study. | 2022 May |
1 |
| 44 |
35496952 | Secondary Hypogammaglobulinemia in Patients with Chronic Lymphocytic Leukemia Receiving Ibrutinib Therapy. | 2022 Apr |
1 |
| 45 |
35507054 | BTK inhibitor selection for chronic lymphocytic leukemia: which drug for which patient? | 2022 May |
1 |
| 46 |
35514998 | Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome. | 2022 |
1 |
| 47 |
35571529 | Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse. | 2022 |
1 |
| 48 |
35573643 | Clustering extent-dependent differential signaling by CLEC-2 receptors in platelets. | 2022 Mar |
1 |
| 49 |
35587148 | Improved Electrophile Design for Exquisite Covalent Molecule Selectivity. | 2022 Jun 17 |
5 |
| 50 |
35597428 | BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells. | 2022 Aug |
1 |